1,952 Shares in Illumina, Inc. $ILMN Purchased by SteelPeak Wealth LLC

SteelPeak Wealth LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,952 shares of the life sciences company’s stock, valued at approximately $534,000.

Several other hedge funds have also recently bought and sold shares of ILMN. Fiduciary Financial Advisors purchased a new stake in Illumina during the second quarter worth approximately $26,000. MCF Advisors LLC increased its position in shares of Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina in the second quarter worth $32,000. Rakuten Securities Inc. purchased a new position in shares of Illumina in the 2nd quarter valued at $33,000. Finally, Elevation Wealth Partners LLC raised its stake in shares of Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after acquiring an additional 84 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In related news, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the sale, the director owned 770,350 shares of the company’s stock, valued at $168,244,440. The trade was a 13.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,061,850 shares of company stock valued at $436,479,102. Company insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Sunday, October 11th. Guggenheim increased their price target on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Stifel Nicolaus increased their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Leerink Partners raised their price objective on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Finally, Canaccord Genuity Group boosted their price objective on Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $231.88.

Illumina Stock Up 0.0%

Shares of NASDAQ:ILMN opened at $262.66 on Tuesday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 52-week low of $94.00 and a 52-week high of $309.35. The company has a 50 day moving average of $235.94 and a two-hundred day moving average of $187.45. The company has a market capitalization of $39.66 billion, a price-to-earnings ratio of 50.98, a price-to-earnings-growth ratio of 3.72 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.